Opioid Receptor Agonist Market By Drug Type (Full Opioid Agonists, Partial Opioid Agonists, Mixed Agonist–Antagonists); By Receptor Type (Mu Opioid Receptor Agonists, Kappa Opioid Receptor Agonists, Delta Opioid Receptor Agonists); By Application (Pain Management, Opioid Use Disorder Treatment, Anesthesia and Perioperative Care); By Route of Administration (Oral, Injectable, Transdermal); By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Specialty Pharmacies); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

How Are Pain Management Needs, Opioid Use Disorder Treatment, and Emerging Therapies Shaping the Opioid Receptor Agonist Market? – (Updated On: 9th-Nov-2026)

According to Strategic Market Research, the Global Opioid Receptor Agonist Market was valued at USD 12.40 billion in 2025 and is projected to reach USD 15.25 billion by 2032, growing at a CAGR of 3.0% during 2026–2032. The market includes opioid receptor agonist medicines used for moderate to severe pain management and opioid use disorder treatment. Morphine, fentanyl, oxycodone, methadone, and buprenorphine are important medicines within this market. Continued medical use of opioid analgesics and established treatment with methadone and buprenorphine support demand, while declining opioid prescriptions and generic competition constrain growth.

 

The United States has a substantial patient population requiring opioid dependence treatment. According to the Substance Abuse and Mental Health Services Administration (SAMHSA), approximately 4.8 million Americans aged 12 and older had opioid use disorder in 2024, while approximately 818,000 received medication treatment for the condition.

 

Prescription activity provides direct evidence of opioid agonist medicine utilization. According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 120.41 million opioid prescriptions were dispensed through U.S. retail pharmacies in 2024, compared with 125.49 million in 2023, representing a decline of approximately 4.0%. Separately, approximately 15.43 million buprenorphine prescriptions were dispensed in 2024, compared with 15.66 million in 2023. These figures demonstrate substantial utilization of opioid medicines, although methadone administered through specialized opioid treatment programs is not fully represented in retail prescription statistics.

 

Buprenorphine is becoming easier to obtain in the United States for people receiving treatment for opioid addiction. According to a CDC study published in August 2026, the share of pharmacies providing buprenorphine increased from 64.8% in 2019 to 72.4% in 2025 in urban areas and from 64.9% to 80.0% in rural areas. This means more pharmacies are making the medication available, especially in rural communities. In 2025, emergency departments also provided buprenorphine during approximately 11% of eligible visits in urban areas and 10% in rural areas.

 

International opioid agonist treatment activity provides additional evidence of medicine utilization. According to the Australian Institute of Health and Welfare, approximately 58,000 clients received opioid pharmacotherapy in Australia on a snapshot day in 2023, with methadone and buprenorphine representing the principal treatment medicines

 

FDA-approved opioid agonist medicines support both pain management and opioid dependence treatment. The U.S. Food and Drug Administration (FDA) recognizes methadone and buprenorphine as approved medicines for opioid use disorder. Approved buprenorphine products include SUBLOCADE, a monthly extended-release injection; BRIXADI, available in weekly and monthly injectable formulations; and SUBOXONE, a buprenorphine/naloxone combination used for opioid dependence treatment. FDA-approved opioid analgesics also include morphine, oxycodone, and fentanyl formulations for specified pain management indications.

 

Recent regulatory developments have expanded treatment options for opioid dependence. In May 2023, the FDA approved BRIXADI, introducing weekly and monthly extended-release buprenorphine injections for eligible patients with opioid use disorder. In May 2023, the FDA also approved OPVEE, a nalmefene nasal spray for opioid overdose reversal. However, OPVEE is an opioid antagonist and is not part of the opioid receptor agonist market. In April 2026, the World Health Organization updated its recommendations for opioid dependence treatment, reaffirming methadone and oral buprenorphine while extending recommendations to long-acting injectable buprenorphine.

 

Competition remains active across generic opioid analgesics and branded addiction treatments. Indivior markets SUBLOCADE, a monthly extended-release buprenorphine injection, while Camurus developed BUVIDAL and BRIXADI, weekly and monthly buprenorphine formulations. Teva and Pfizer participate in established opioid analgesic categories. Generic competition limits differentiation in conventional pain medications, while long-acting formulations create opportunities in opioid use disorder treatment.

 

Overall, the projected expansion of the Global Opioid Receptor Agonist Market from USD 12.40 billion in 2025 to USD 15.25 billion by 2032 is supported by continued opioid analgesic use and established treatment activity involving methadone and buprenorphine. The approximately 120.41 million U.S. opioid prescriptions in 2024, 15.43 million buprenorphine prescriptions, and 58,000 Australian opioid pharmacotherapy clients in 2023 demonstrate medicine utilization across different healthcare systems. FDA-approved long-acting buprenorphine products, wider treatment availability, and updated international recommendations provide additional opportunities, while declining opioid prescription volumes and generic competition remain important market constraints.

 

Which Leading and Emerging Subsegments Are Shaping the Opioid Receptor Agonist Market?

By Drug Type: Severe Pain Sustains Full Agonists as Buprenorphine Expands in Addiction Care

Leading Subsegment: Full Opioid Agonists

Full opioid agonists hold a leading position in the Global Opioid Receptor Agonist Market, accounting for an estimated 65% market share, valued at USD 8.060 billion in 2025, with a projected CAGR of 2.05% during 2026–2032. Medications such as morphine, fentanyl, and oxycodone fully activate opioid receptors, primarily mu (μ) receptors, providing strong pain relief for patients experiencing severe acute pain, postoperative pain, and cancer-related pain. Their established clinical use supports market leadership, although prescribing restrictions, addiction risks, and increasing preference for non-opioid alternatives limit growth.

Fastest-Growing Subsegment: Partial Opioid Agonists

Partial opioid agonists account for an estimated 29% share of the global Opioid Receptor Agonist Market, valued at USD 3.596 billion in 2025, and are projected to register the fastest CAGR of 5.15% during 2026–2032. Medications such as buprenorphine provide controlled activation of opioid receptors, producing moderate effects compared with full opioid agonists. Their growing use in opioid use disorder treatment and selected pain management applications supports market expansion, particularly as healthcare providers increasingly adopt buprenorphine-based therapies for long-term treatment and recovery support.

 

By Receptor Type: Mu Agonists Anchor Pain Care as Kappa Research Targets New Uses

Leading Subsegment: Mu (μ) Opioid Receptor Agonists

Mu (μ) opioid receptor agonists hold a dominant position in the global Opioid Receptor Agonist Market, accounting for an estimated 94% market share, valued at USD 11.656 billion in 2025, and are projected to grow at a CAGR of 2.85% during 2026–2032. Their widespread use in managing moderate to severe pain, including postoperative pain, cancer-related pain, and chronic pain, supports their market leadership. Established medications such as morphine, fentanyl, and oxycodone remain important treatment options across hospitals, specialty clinics, and palliative care settings.

Fastest-Growing Subsegment: Kappa (κ) Opioid Receptor Agonists

Kappa (κ) opioid receptor (KOR) agonists account for an estimated 5% share of the Global Opioid Receptor Agonist Market, valued at USD 0.620 billion in 2025, and are projected to grow at a CAGR of 5.65% during 2026–2032. KOR agonists act as alternatives to traditional mu-opioid receptor agonists, such as morphine, offering potential applications in pain management and pruritus treatment. Growing clinical interest in selective and peripherally acting KOR agonists is supporting pharmaceutical development, particularly for treatments aimed at reducing conventional opioid-related adverse effects.

 

By Application: Established Pain Care and Wider Addiction Treatment Access Shape Demand

Leading Subsegment: Pain Management

Pain management accounts for an estimated 69% share of the Global Opioid Receptor Agonist Market, valued at USD 8.556 billion in 2025, and is projected to grow at a CAGR of 2.20% during 2026–2032. Opioid receptor agonists are widely used to manage moderate to severe pain by activating opioid receptors, particularly mu (μ) receptors, in the central and peripheral nervous systems. Their established role in postoperative pain relief, cancer-related pain management, and selected chronic pain conditions supports their continued clinical use under appropriate medical supervision.

Fastest-Growing Subsegment: Opioid Use Disorder Treatment

Opioid use disorder treatment accounts for an estimated 22% share of the Global Opioid Receptor Agonist Market, valued at USD 2.728 billion in 2025, and is projected to register the fastest CAGR of 5.45% during 2026–2032. Opioid receptor agonists, particularly methadone and buprenorphine, play an important role in managing opioid dependence by reducing withdrawal symptoms, controlling drug cravings, and supporting long-term recovery. Increasing access to medication-assisted treatment, expansion of addiction treatment programs, and greater clinical adoption of maintenance therapies are supporting market growth.

 

By Route of Administration: Oral Therapies Support Long-Term Care as Injectables Gain Ground

Leading Subsegment: Oral

Oral administration holds a leading position in the Opioid Receptor Agonist Market, accounting for an estimated 61% market share, valued at USD 7.564 billion in 2025, and is projected to grow at a CAGR of 2.45% during 2026–2032. Oral opioid receptor agonists are widely used for managing moderate to severe pain, treating opioid use disorder through medications such as methadone and buprenorphine, and controlling gastrointestinal conditions such as diarrhea. Their established clinical use, convenient administration, and suitability for long-term treatment support continued market growth.

Fastest-Growing Subsegment: Injectable

Injectable formulations account for an estimated 30% share of the Opioid Receptor Agonist Market, valued at USD 3.720 billion in 2025, and are projected to register the fastest CAGR of 4.35% during 2026–2032. Injectable opioid receptor agonists play an important role in managing severe pain in hospitals, emergency departments, and surgical settings, where rapid pain relief is essential. Long-acting injectable formulations, including extended-release buprenorphine, also support opioid use disorder treatment by improving medication adherence and reducing the frequency of administration.

 

By Distribution Channel: Retail Pharmacies Handle Routine Prescriptions as Specialty Pharmacies Support Long-Acting Therapies

Leading Subsegment: Retail Pharmacies

Retail pharmacies represent the leading distribution channel in the Opioid Receptor Agonist Market, accounting for an estimated 49% market share, valued at USD 6.076 billion in 2025, and are projected to grow at a CAGR of 2.45% during 2026–2032. Retail pharmacies serve as primary community access points for patients prescribed opioid receptor agonists for pain management and other approved medical conditions. Their widespread availability, prescription dispensing services, pharmacist guidance, and support for ongoing medication management contribute to their leading position in the market.

Fastest-Growing Subsegment: Specialty Pharmacies

Specialty pharmacies play an important role in dispensing and managing opioid receptor agonists, particularly complex, high-risk, and long-acting formulations requiring specialized patient support. Specialty pharmacies accounted for an estimated 13% share of the global Opioid Receptor Agonist Market, equivalent to USD 1.612 billion in 2025, and are projected to register the fastest CAGR of 5.35% during 2026–2032. Growth is supported by increasing use of long-acting opioid therapies, specialized medication management, patient monitoring, and adherence programs for individuals receiving prolonged opioid treatment.

 

By Geography: North American Prescribing Rules and Asia-Pacific Treatment Access Shape Growth

Leading Region: North America

North America dominates the Opioid Receptor Agonist Market, accounting for an estimated 43% market share, valued at USD 5.332 billion in 2025, and is projected to grow at a CAGR of 2.55% during 2026–2032. The region's leading position reflects the widespread clinical use of opioid receptor agonists for managing moderate to severe pain, particularly in surgical care, cancer treatment, and chronic pain management. However, strict prescribing regulations, opioid misuse prevention initiatives, and ongoing public health concerns continue to influence clinical practices and market growth.

Fastest-Growing Region: Asia-Pacific

Asia-Pacific region accounts for an estimated 22% share of the global Opioid Receptor Agonist Market, valued at USD 2.728 billion in 2025, and is projected to register the fastest regional CAGR of 4.55% during 2026–2032. Growth is supported by increasing use of opioid receptor agonists in clinical pain management and opioid use disorder (OUD) treatment. Expanding access to hospital-based pain relief, greater availability of opioid substitution therapies, and improving addiction treatment services across China, India, Japan, and Australia are contributing to regional market expansion.

 

Which Companies Are Shaping the Competitive Landscape of the Opioid Receptor Agonist Market?

Indivior Plc: SUBLOCADE Drives Buprenorphine Revenue

Indivior Plc is a leading specialist in opioid use disorder treatment, with an established portfolio of buprenorphine-based medications. Its principal product, SUBLOCADE, is a once-monthly extended-release buprenorphine injection used to treat moderate-to-severe opioid use disorder in eligible patients. The company also markets SUBOXONE Film, a buprenorphine/naloxone treatment. SUBLOCADE represents an important commercial development because it provides a long-acting alternative to daily medication, supporting treatment continuity and reducing the need for frequent dosing.

Indivior reported approximately USD 1.2 billion in total net revenue in 2024, including approximately USD 765 million from SUBLOCADE. These historical company-reported figures demonstrate its substantial commercial presence in opioid dependence treatment, although they do not establish leadership across the entire opioid receptor agonist market, which also includes conventional analgesics and anesthesia medications.

Indivior's more recent results further strengthen its position in addiction treatment. In 2025, the company reported USD 1.239 billion in total net revenue, including USD 856 million from SUBLOCADE, an increase of 13% compared with 2024. SUBLOCADE contributed approximately 69% of total company revenue, demonstrating the commercial importance of long-acting buprenorphine therapy.

Other Key Companies and Their Market Roles:

• Camurus: Develops BUVIDAL, a weekly and monthly extended-release buprenorphine treatment for opioid dependence, with BRIXADI marketed in the United States through Braeburn.

• Alkermes: Markets VIVITROL, an extended-release naltrexone injection used in opioid relapse prevention; it is an opioid receptor antagonist rather than an agonist.

• Teva Pharmaceutical Industries Ltd.: Participates in the opioid analgesics market through generic prescription medications, including products used for moderate-to-severe pain.

• Pfizer Inc.: Maintains a presence in opioid-based hospital analgesia and anesthesia through established injectable medications, including fentanyl formulations.

 

Which Emerging Drug Pipelines and Receptor-Targeted Therapies Are Reshaping the Opioid Receptor Agonist Market?

Biased Kappa Opioid Receptor Agonists

KSB-200 – Toray Industries: KSB-200 is described in the supplied pipeline information as an investigational oral kappa opioid receptor agonist for postoperative pain. Its proposed approach involves preferential activation of G-protein signaling to potentially reduce adverse effects associated with conventional kappa agonists. Clinical efficacy, development status, and safety advantages require confirmation.

Nalfurafine Hydrochloride (TRK-820): Nalfurafine is a selective kappa opioid receptor agonist with established use for certain forms of severe pruritus in Japan. Its clinical experience provides a foundation for further investigation of kappa-targeted treatments, although its role in postoperative pain remains unestablished.

Nociceptin Receptor Agonists

Grünenthal's Investigational NOP Agonist: Research into nociceptin/orphanin FQ peptide (NOP) receptors represents an alternative approach to conventional opioid analgesia. The supplied pipeline information describes an early-stage Grünenthal program exploring acute pain treatment. NOP-targeted compounds may offer differentiated pain management options, but claims of reduced respiratory depression or abuse potential require supporting clinical evidence.

Delta Opioid Receptor Agonists

Aprepitant and Mavorixafor – Exploratory Research: These existing medicines have been identified in computational research as potential candidates for further investigation of delta opioid receptor activity. However, neither is an established delta opioid receptor agonist. Their relevance remains preliminary, and additional laboratory and clinical evidence would be necessary before considering them commercially viable delta-targeted pain treatments.

Multi-Target and Biased Signaling Therapies

SR-17018 and Cyclic Peptidomimetics: Experimental compounds such as SR-17018 and RP-170, RP-171, and RP-172 represent research into alternative opioid receptor signaling and multi-target activity. These programs seek to preserve analgesic effects while potentially reducing tolerance and other opioid-related adverse effects. They remain early-stage research approaches without established commercial applications.

Additional Clinical Pipeline Developments:

• HSK21542 – Haisco Pharmaceutical: HSK21542 is a peripheral kappa opioid receptor agonist developed for postoperative pain. Two Phase III trials in China were reported in 2025, providing more advanced clinical evidence than many exploratory receptor-targeted programs.

• Grünenthal's NOP Agonist – Phase II Advancement: In October 2026, Grünenthal announced that its investigational NOP agonist had entered Phase II testing. The study plans to enroll up to 400 patients following bunionectomy surgery, building on Phase I results involving 113 healthy participants. This represents a measurable clinical milestone for NOP-targeted analgesics.

 

Analyst Commentary: Where Can Opioid Agonist Developers Differentiate as Prescribing Tightens?

The opioid receptor agonist market is increasingly divided between established pain medications and specialized opioid use disorder therapies. Long-acting buprenorphine formulations offer stronger commercial differentiation than conventional generic opioids, while prescribing restrictions limit expansion in pain management. Companies developing clinically proven, safer analgesics and differentiated addiction treatments are better positioned to capture higher-value opportunities.

 

Opioid Receptor Agonist Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 12.40 Billion
Revenue Forecast in 2032	USD 15.25 Billion
Overall Growth Rate	CAGR of 3.0% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million/Billion, CAGR (2026 – 2032)
Segmentation	By Drug Type, By Receptor Type, By Application, By Route of Administration, By Distribution Channel, By Geography
By Drug Type	Full Opioid Agonists, Partial Opioid Agonists, Mixed Agonist–Antagonists
By Receptor Type	Mu Opioid Receptor Agonists, Kappa Opioid Receptor Agonists, Delta Opioid Receptor Agonists
By Application	Pain Management, Opioid Use Disorder Treatment, Anesthesia and Perioperative Care
By Route of Administration	Oral, Injectable, Transdermal
By Distribution Channel	Retail Pharmacies, Hospital Pharmacies, Specialty Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Continued use of opioid analgesics for moderate to severe pain, established use of methadone and buprenorphine for opioid use disorder, wider pharmacy access to buprenorphine, and availability of extended-release injectable formulations
Customization Option	Available upon request